Caracterización y resultados de pacientes tratados con apremilast en la práctica clínica habitual española: resultados del estudio APPRECIATE

Herranz, Pedro; Trasobares, Lidia; Mateu, A.; Martínez, E.; Ruiz‐Villaverde, Ricardo; Baniandrés, Ofelia; Díaz, J. Mataix; Jiménez-Gómez, N.; Serra, M.Á.; Genao, D.P. Ruiz; Rivera, Noelia; Tercedor-Sánchez, J.; Garcia, C.; Cordey, Myriam; Herrera‐Acosta, Enrique

doi:10.1016/j.ad.2021.05.010

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other real‐world studies of apremilast use in Europe showed similar results, with 90.9%–99.0% of patients achieving PBI ≥ 1 at 6 months, compared to 90.8% in this study 5,22,29 (Supporting Information: Table ). In a Spanish cohort of patients receiving apremilast for the treatment of psoriasis, 83.2% of patients overall and 100% of those who continued on apremilast achieved PBI ≥ 1 30 . These data indicate that apremilast treatment meets most patients' needs and expectations and provide useful information regarding its effectiveness from the patients' perspective.…”

Section: Discussionmentioning

confidence: 73%

“…In a Spanish cohort of patients receiving apremilast for the treatment of psoriasis, 83.2% of patients overall and 100% of those who continued on apremilast achieved PBI ≥ 1. 30 These data indicate that apremilast treatment meets most patients' needs and expectations and provide useful information regarding its effectiveness from the patients' perspective.…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

Cueva‐Dobao

Armesto

Montesinos

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundDespite the proven efficacy and safety of apremilast to treat plaque psoriasis (PsO), data regarding its real‐world use and patient‐perceived benefits are limited.ObjectivesDescribe apremilast use, persistence and tolerability, and its patient‐perceived benefits and effectiveness in patients with PsO in Spanish clinical practice.MethodsObservational, prospective, multicenter study including patients with moderate‐to‐severe PsO initiating apremilast 3 months (±4 weeks) before enrolment, after at least one conventional systemic therapy and no biologics. Prospective data were collected 3 (at enrolment), 6 and 12 months (±4 weeks) after apremilast initiation. Primary outcome was a Patient Benefit Index (PBI) score ≥1 (minimum clinically relevant benefit) at 6 months.ResultsOf 153 patients enroled, 119 were included in the analysis; mean (standard deviation [SD]) age, 52.8 (15.2) years. At apremilast initiation, mean (SD) Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were 8.3 (4.9) and 10.5 (6.8), respectively. Most patients (81%) had comorbidities; PsO manifestations included scalp (47% of patients), palmoplantar (26%), nails (24%) and genitals (11%). Over three‐quarters (86%) of patients were continuing apremilast at Month 6, with most (91%) achieving a PBI ≥ 1% and 43% achieving a PBI ≥ 3; two‐thirds (68%) were continuing apremilast at Month 12, with 91% and 42% achieving a PBI ≥ 1 and ≥3, respectively. Mean (SD) pruritus scores decreased from 54.5 (32.1) at apremilast initiation to 23.4 (27.0) at Month 12; 57%, 69% and 69% of patients achieved a DLQI 0‒1, PASI < 3 and BSA < 3, respectively. Adverse events were consistent with the known safety profile.ConclusionsPatients initiating apremilast after conventional systemic therapy in Spanish clinical practice had moderate PsO at bothersome/visible locations and impaired quality of life. Most patients remained on apremilast for 12 months, with improved patient‐reported outcomes and skin involvement, and almost all patients reported some clinical benefit. Apremilast was well tolerated without new safety signals.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 79%

Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

Cueva‐Dobao

Armesto

Montesinos

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

show abstract

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe

et al. 2023

View full text Add to dashboard Cite

Introduction The broad and sustained efficacy of apremilast for psoriasis has been demonstrated in randomized and real-world observational studies. Data from Central and Eastern Europe (CEE) are lacking. Moreover, apremilast use in this region is limited by country-specific reimbursement criteria. This is the first study to report data on the real-world use of apremilast in the region. Methods APPRECIATE (NCT02740218) was an observational, retrospective, cross-sectional study assessing psoriasis patients 6 (± 1) months after apremilast treatment initiation. The study aimed to describe the characteristics of patients with psoriasis receiving apremilast, estimate treatment outcomes, including Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI), and assess dermatologists' and patients' perspectives on treatment using questionnaires including the Patient Benefit Index (PBI). Adverse event reports were taken from the medical records. Results Fifty patients (Croatia: 25; Czech Republic: 20; Slovenia: 5) were enrolled. In patients continuing apremilast at 6 (± 1) months, mean (± SD) PASI score was reduced from 16.2 ± 8.7 points at treatment initiation to 3.1 ± 5.2 at 6 (± 1) months; BSA from 11.9% ± 10.3% to 0.8% ± 0.9%; DLQI from 13.7 ± 7.4 points to 1.6 ± 3.2. PASI 75 was reached by 81% of patients. Physicians reported that the overall treatment success fulfilled their expectations in more than two thirds of patients (68%). At least three-quarters of patients reported apremilast had a quite or very high benefit on the needs they identified as being most important. Apremilast was well tolerated; no serious or fatal adverse events were identified. Conclusion Apremilast was effective in reducing skin involvement and improving quality of life in CEE patients having severe disease. Treatment satisfaction among physicians and patients was very high. These data add to the growing body of evidence showing consistent effectiveness of apremilast across the continuum of psoriasis disease severity and manifestations. Trial registration ClinicalTrials.gov identifier, NCT02740218. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02468-3.

show abstract

Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment

Pinto-Pulido

Lario

González‐Cañete

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Apremilast is an oral small molecule approved for the treatment of psoriasis, psoriatic arthritis and oral ulcers associated with Behçet's disease. This research was conducted to describe the characteristics of patients who received treatment with apremilast for a skin disorder, either before, during, or after a biological treatment, with the aim of analyze the reasons that lead to start this drug in real clinical practice or suspend it for another. A total of 41 patients were enrolled: nine (22.0%) had received biological treatment prior to apremilast, seven (17.0%) both before and after apremilast and 25 (61.0%) after apremilast. One patient received concomitant treatment with adalimumab and apremilast. Most patients (85.4%) received apremilast as treatment for psoriasis. Reasons for starting apremilast were lack of efficacy with previous treatments (85.4%) and adverse effects or contraindication to previous treatments (14.6%), without statistically significant differences between patients who had received a previous biologic and those who had not. Drug survival was not influenced by previous biological treatment, but we found an increased risk of drug discontinuation in patients with chronic kidney disease (log-rank p = 0.028). The main reason of apremilast withdrawal was lack of adequate disease control (60.0%), most of whom required treatment with biologics. Therefore, despite the extensive development of new therapies for psoriasis and other dermatological conditions, apremilast is a widely used drug even in patients who are candidates for biologic treatment.Its initiation is more frequent due to poor disease control than because of other therapies contraindications.

show abstract

Caracterización y resultados de pacientes tratados con apremilast en la práctica clínica habitual española: resultados del estudio APPRECIATE

Cited by 3 publications

References 15 publications

Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe

Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment

Contact Info

Product

Resources

About